TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).


Options:
A: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
B: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).


Options:
A: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
D: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-naive Type 2 Diabetes Patients Uncontrolled on Oral Hypoglycemic Agent Treatment Initiating Basal Insulin Therapy With Either Insulin Glargine or NPH Insulin
Brief Summary: Primary Objective:

To investigate the impact of insulin glargine versus Neutral Protamine Hagedorn basal insulin on a composite diabetes related quality of life score (DRQoL).

Secondary Objective:

A comparison of combination therapy with insulin glargine versus Neutral Protamine Hagedorn basal insulin from baseline to endpoint in terms of:

* Glycaemic parameters: 7 blood glucose profiles
* Incidence of confirmed symptomatic hypoglycemia as well as confirmed severe hypoglycemia
* Change in lipid status


Options:
A: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
C: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
D: Arm Label: 1 - Insulin glargine QHS; Type: EXPERIMENTAL; Interventions: Drug: 1- Insulin glargine QHS | Arm Label: 2 - Insulin glargine QAM; Type: EXPERIMENTAL; Interventions: Drug: 2 - Insulin glargine QAM | Arm Label: 3 - NPH Insulin QHS; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 - NPH insulin QHS | Intervention Type: DRUG; Name: 1- Insulin glargine QHS; Assigned to Arm(s): 1 - Insulin glargine QHS | Intervention Type: DRUG; Name: 2 - Insulin glargine QAM; Assigned to Arm(s): 2 - Insulin glargine QAM | Intervention Type: DRUG; Name: 3 - NPH insulin QHS; Assigned to Arm(s): 3 - NPH Insulin QHS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Comparative Calcium Absorption and Gastrointestinal Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends"
Brief Summary: The objective is to assess the comparative calcium absorption and gastrointestinal (GI) tolerance in healthy normal term infants fed two commercially available powdered milk-based formulas which contain different fat blends.


Options:
A: Arm Label: Commercially available infant formula A; Type: EXPERIMENTAL; Interventions: Other: Infant Formula milk based | Arm Label: Commercially available infant formula B; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula milk based | Intervention Type: OTHER; Name: Infant Formula milk based; Assigned to Arm(s): Commercially available infant formula A | Intervention Type: OTHER; Name: Infant formula milk based; Assigned to Arm(s): Commercially available infant formula B
B: Arm Label: standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: modified infant formula; Type: EXPERIMENTAL; Interventions: Other: modified infant formula | Arm Label: breast milk; Type: OTHER; Interventions: Other: breast milk | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): standard infant formula | Intervention Type: OTHER; Name: modified infant formula; Assigned to Arm(s): modified infant formula | Intervention Type: OTHER; Name: breast milk; Assigned to Arm(s): breast milk
C: Arm Label: low docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: low docosahexaenoic acid formula | Arm Label: medium docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: medium docosahexaenoic acid formula | Arm Label: high docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: high docosahexaenoic acid formula | Arm Label: human milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: low docosahexaenoic acid formula; Assigned to Arm(s): low docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: medium docosahexaenoic acid formula; Assigned to Arm(s): medium docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: high docosahexaenoic acid formula; Assigned to Arm(s): high docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: breast milk; Assigned to Arm(s): human milk
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nutrition | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrition; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA (Percutaneous Transluminal Angioplasty) for the Treatment of Below the Knee Critical Limb Ischemia
Brief Summary: This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard (Percutaneous Transluminal Angioplasty) PTA balloon. Patients will be followed with pre-study, post-study, and follow-up evaluations.


Options:
A: Arm Label: Lutonix Catheter; Type: EXPERIMENTAL; Interventions: Device: Lutonix Catheter | Arm Label: Standard uncoated Balloon Angioplasty Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard uncoated Balloon Angioplasty Catheter | Intervention Type: DEVICE; Name: Lutonix Catheter; Assigned to Arm(s): Lutonix Catheter | Intervention Type: DEVICE; Name: Standard uncoated Balloon Angioplasty Catheter; Assigned to Arm(s): Standard uncoated Balloon Angioplasty Catheter
B: Arm Label: Drug Eluting Balloon; Type: EXPERIMENTAL; Interventions: Device: IN.PACT Amphirion | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA | Intervention Type: DEVICE; Name: IN.PACT Amphirion; Assigned to Arm(s): Drug Eluting Balloon | Intervention Type: DEVICE; Name: Standard PTA; Assigned to Arm(s): Standard PTA
C: Arm Label: ENERGY-Population; Type: N/A; Interventions: Device: Pro Kinetic Energy bare metal stent | Intervention Type: DEVICE; Name: Pro Kinetic Energy bare metal stent; Assigned to Arm(s): ENERGY-Population
D: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Brief Summary: Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial was to assess the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This was an event driven trial.


Options:
A: Arm Label: tiotropium 5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5 mcg | Arm Label: tiotropium 2.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg; Assigned to Arm(s): tiotropium 2.5 mcg | Intervention Type: DRUG; Name: tiotropium 5 mcg; Assigned to Arm(s): tiotropium 5 mcg
B: Arm Label: QMF149 Twisthaler® 500/400; Type: EXPERIMENTAL; Interventions: Drug: QMF149 Twisthaler® | Arm Label: Mometasone Twisthaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone Twisthaler® | Intervention Type: DRUG; Name: QMF149 Twisthaler®; Assigned to Arm(s): QMF149 Twisthaler® 500/400 | Intervention Type: DRUG; Name: Mometasone Twisthaler®; Assigned to Arm(s): Mometasone Twisthaler®
C: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate, Drug: Vilanterol | Arm Label: FP/S OR BUD/F; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Salmeterol, Drug: Budesonide, Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): FP/S OR BUD/F

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Brief Summary: Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial was to assess the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This was an event driven trial.


Options:
A: Arm Label: QMF149 Twisthaler® 500/400; Type: EXPERIMENTAL; Interventions: Drug: QMF149 Twisthaler® | Arm Label: Mometasone Twisthaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone Twisthaler® | Intervention Type: DRUG; Name: QMF149 Twisthaler®; Assigned to Arm(s): QMF149 Twisthaler® 500/400 | Intervention Type: DRUG; Name: Mometasone Twisthaler®; Assigned to Arm(s): Mometasone Twisthaler®
B: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
C: Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium, Device: Respimat, Device: Breezehaler | Arm Label: glycopyrronium; Type: EXPERIMENTAL; Interventions: Drug: glycopyrronium, Device: Respimat, Device: Breezehaler | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: glycopyrronium; Assigned to Arm(s): glycopyrronium | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): glycopyrronium, tiotropium | Intervention Type: DEVICE; Name: Breezehaler; Assigned to Arm(s): glycopyrronium, tiotropium
D: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Walking Away From Type 2 Diabetes: a Cluster Randomized Controlled Trial to Investigate the Effect of Structured Education on Walking Activity in Those With a High Risk of Developing Type 2 Diabetes
Brief Summary: Diabetes is a debilitating chronic disease reaching epidemic proportions. Lack of physical activity is a key factor driving this epidemic and it is therefore vital that workable methods of encouraging people to exercise and reducing inactivity are developed and tested if we are to stem the rising tide of diabetes.

This cluster randomised controlled trial will investigate whether a person-centred group educational programme can increase walking activity and reduce the risk of developing diabetes in high-risk individuals identified in primary care settings. In total 804 patients will be recruited to the study. Physical activity levels, glucose control, incidence of type 2 diabetes and anthropometric measurements (e.g. weight) will be tested on an annual basis over three years.

This trial will be the first to test the feasibility, efficacy and value for money of a physical activity intervention aimed at reducing the risk of diabetes in a community setting in a multi-ethnic population in the UK.

Primary research hypothesis: A pragmatic structured education programme aimed at promoting walking activity initiates long-term increases in physical activity in individuals identified through a risk score as having an increased risk of developing type 2 diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
B: Arm Label: Blood Test Group; Type: EXPERIMENTAL; Interventions: Behavioral: Blood Test Group Intervention | Arm Label: Brochure Group (usual care); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brochure Group Intervention | Intervention Type: BEHAVIORAL; Name: Blood Test Group Intervention; Assigned to Arm(s): Blood Test Group | Intervention Type: BEHAVIORAL; Name: Brochure Group Intervention; Assigned to Arm(s): Brochure Group (usual care)
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: optimised treatment | Intervention Type: PROCEDURE; Name: optimised treatment; Assigned to Arm(s): Intervention
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Structured Education | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Information | Intervention Type: BEHAVIORAL; Name: Structured Education; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Written Information; Assigned to Arm(s): Control

Answer: D